Pharma Focus Europe’s Post

Accelerating Drug Discovery: IDM Insight's AI powered Solution to Research Roadblocks Powered by AI: IDM Insight Seamlessly integrates advanced algorithms and machine learning to accelerate drug discovery. Prioritize compounds and targets based on therapeutic potential and utilize our Generative AI tool for novel molecule design. Access over 2 million compounds, from preclinical to approved drugs, in one comprehensive platform. Our databases stand out with unmatched comprehensiveness, integrating data from diverse sources for confident decision-making. Dive into physico-chemical properties, bioactivities, and more, aiding rational drug design. Explore interconnected databases for a holistic view of biological pathways and disease mechanisms, supporting drug readdressing and repurposing campaigns. Read the full article to discover how IDM Insight is shaping the future of medicinal chemistry. #DrugDiscovery #MedicinalChemistry #AIIntegration #ResearchInnovation #IDMInsight #ScienceAdvancements

In today's fast-paced world, Artificial Intelligence (AI) is reshaping the landscape of drug discovery. This groundbreaking article by 𝐕𝐢𝐝𝐮𝐬𝐡𝐢 𝐘𝐚𝐝𝐚𝐯, Ananya Anurag Anand, and Sintu Samanta dives deep into how platforms like AtomNet and Insilico Medicine are enhancing target identification and molecular simulations, paving the way for innovative, 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬. 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞 𝐢𝐧 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐦𝐞𝐫𝐢𝐜𝐚, 𝐌𝐚𝐠𝐚𝐳𝐢𝐧𝐞 𝐈𝐬𝐬𝐮𝐞 𝟎𝟒. 👉 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞: https://lnkd.in/g2sc9DeZ 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐭𝐡𝐞 𝐞-𝐛𝐨𝐨𝐤 𝐧𝐨𝐰: https://lnkd.in/gdXUhnQ4 𝐕𝐢𝐬𝐢𝐭 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐦𝐞𝐫𝐢𝐜𝐚: https://lnkd.in/duKnzVCp #DrugDiscovery #AIinHealthcare #Innovation #Pharmaceuticals #PersonalizedMedicine #Research #Bioinformatics #Healthcare #AntibioticResistance #MolecularSimulations #Collaboration #TechForGood #FutureOfMedicine #PharmaFocus #MedicalResearch

𝗧𝗵𝗲 𝟭𝟯𝘁𝗵 𝗔𝗻𝗻𝘂𝗮𝗹 𝗛𝗼𝘂𝘀𝗲 𝗼𝗳 𝗣𝗵𝗮𝗿𝗺𝗮 𝗮𝗻𝗱 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 on September 3, 2024, in #FrankfurtamMain is coming up - and we are attending! With Dr. Daniel-Timon Spanka talking about data quality and increased efficiency, he will discuss how our AI-software #Meteor transforms clinical data reviews and supports the work of data management experts in the pharmaceutical industry and in CROs. Currently, a lot of time is required to manually check all texts collected in clinical studies. Meteor presents a valuable solution with efficient clinical data reviews, saving time and reducing error rates significantly with the help of AI. Catch us in Frankfurt and schedule a meeting with our experts in data science to discuss the use of artificial intelligence in medical research. Hanno Härtlein Alex Heinz Dr. Paul W. Dr. Benedikt Linder Dr. Juan M. Guerra #HouseofPharma #Healthcare #ClinicalTrials

Call for Papers — Amplify journal! With the surge of competing clinical trials targeting identical diseases and patient pools, achieving trial success and securing regulatory approval has become increasingly complex. The industry is facing a major dilemma: how to balance future innovation and competitiveness with current operational efficiencies. In an upcoming issue of Amplify Guest Editors Ulrica Sehlstedt, Ben Enejo, and Franziska Thomas of Arthur D. Little invite articles exploring innovative strategies and approaches to expedite and streamline #clinicaltrials to improve patient centricity and drive successful outcomes. 👉 Visit https://lnkd.in/euud7ni8 for more information and to send your abstract for consideration. #callforpapers #clinicaltrials #pharma #pharmaceuticalindustry #innovation #clinicalresearch #therapies #patientcentricity #AI #technologies #amplify #publishing

Generative biology, a fusion of high-throughput automation and AI, is already helping companies like Amgen develop new drug candidates 60% faster than they did five years ago. The key to making this work boils down to robust data sets and active machine-learning models that can be connected to cutting-edge lab equipment. Our innovative AIDDISON platform follows a similar approach. It leverages a wide array of public, commercial, and proprietary experimental datasets to train AI/ML models through reinforcement learning. These models can then predict ADME-Tox properties and propose innovative protein binding. This ensures that novel drug candidates are designed with safety, efficacy, and manufacturability in mind. Generative biology is still a nascent field, but it's an exciting peek at what the future holds. #GenerativeBiology #AIDrugDiscovery #AIDDISON

Are we headed toward the Terminator or the Singularity? | #AI has been the hot topic of the year, and its safety is a frontier far beyond what we currently understand in healthcare. As a Life Sciences community, it's time for us to lead the conversation, focusing on AI's transformative potential rather than irrational fears. Join me, Ron Burns, at the Responsible AI in Clinical Trials Summit on October 8-9, 2024, where I'll share insights into how we can shape this global dialogue. 🔗 Register here: https://lnkd.in/e35wZ7d3 #AIinClinicalTrials #ResponsibleAI #AIinHealthcare #LifeSciences #ClinicalResearch #ClinicalTrials #Pharma #BioTech #MedTech

AI can be used in all aspects of drug development – from discovering biological targets, through developing chemical compounds, to conducting clinical trials. As we expected, this year at JP Morgan's Healthcare Conference, the AI theme was pervasive in almost every presentation, with key players presenting impressive new capabilities relevant to every stage of the value chain. Where does CytoReason fit into this growing trend? We use AI to model disease biology and drug effects. Our Computational Disease Models enable data integration across-the-board for decision making. The main goal is to help pharma enterprises improve probability of phase 2 success. Link to articles in comment below👇 #pharma #computationalbiology #biotech #drugdevelopment #jpm2024

TrialKey shines in Phases 2 and 3 of clinical trials, providing in-depth analysis for optimal outcomes. Our platform offers detailed insights into inclusion/exclusion criteria and drug mechanisms, enhancing the success of these critical trial stages. TrialKey is particularly beneficial in these phases, where determining drug effectiveness and side effects is crucial. With over 350,000 trials registered globally, optimizing trial phases is essential. Book a demo: https://appt.link/minhthu #clinicaltrials #ai #phases2and3 #healthtech #medicalresearch #biotech #innovation #trialdesign #trialsuccess #trialkey

In an interview with China's healthcare publication PharmaCube, Weijie Sun, founder and CEO of DPTechnology, emphasized the potential of AI to break through efficiency, accuracy, and capability limits in many drug development scenarios. On discussing the commercial point of entry and value proposition of AI in pharma, he highlighted that AI in drug development aims to enhance the input-output ratio of original innovations, tackling more key and challenging issues in the industry. He also shared why DPTechnology chose a software model for commercialization, as this approach allows new technologies to be tested and receive feedback quickly and extensively. Looking towards the future of AI in drug development, he is optimistic that computing technology will become an essential infrastructure across all drug research and development fields. #QMportfolio #QMhealthcare #AIInPharma #DrugDevelopment #FutureOfPharma #ShenShiTech #AIInnovation

Geometric deep learning in action! Congratulations to the VantAI team! #geometricdeeplearning